MET and non-small cell lung carcinoma: Our study firstly elucidated that Lico A promoted the ubiquitination of c-Met and revealed a novel antitumor mechanism of the natural product Lico A in NSCLC, indicating that activation of ubiquitination-mediated protein degradation signaling might be a promising antitumor strategy to overcome gefitinib resistance.